Loading clinical trials...

A Comparison of Emtricitabine and Abacavir Used in a Three-Drug Combination in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs | Clinical Trials | Clareo Health

SUSPENDEDPHASE3

A Comparison of Emtricitabine and Abacavir Used in a Three-Drug Combination in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

A Randomized, Open-Label Superiority Trial Comparing Emtricitabine to Abacavir Within a Triple Drug Combination in Antiretroviral-Drug Naive HIV-1 Infected Patients

NCT00002362•Triangle Pharmaceuticals

View on ClinicalTrials.gov

Summary

This study will look at whether emtricitabine is as safe and effective as abacavir (ABC) when taken with stavudine (d4T) and efavirenz (EFV) in patients who have never taken anti-HIV drugs.

Detailed Description

Patients are randomized to receive open-label emtricitabine or ABC in combination with stavudine and efavirenz. Viral load and CD4+ cell counts are compared at Weeks 24 and 48. Patients are followed for 48 weeks.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Are HIV-positive and generally healthy.
•Have a viral load of 5,000 copies/ml or more.
•Have CD4 cell counts of 200 cells/mm3 or more.
•Are age 18 or older.
•Agree to practice sexual abstinence or use effective barrier methods of birth control (such as condoms).
•Have ever taken anti-HIV drugs for 3 days or more.
•Have had certain AIDS-related infections.
•Have had severe diarrhea within the past 30 days.
•Are unable to eat at least 1 meal a day due to nausea, vomiting, or stomach pain.
•Are being treated for active tuberculosis (TB).
+3 more criteria

Locations (10)

Ctr for AIDS Research / Education and Service (CARES)

Sacramento, California, United States

San Francisco Veterans Administration Med Ctr

San Francisco, California, United States

Gary Richmond MD

Fort Lauderdale, Florida, United States

Northstar Med Clinic

Chicago, Illinois, United States

South Jersey Infectious Diseases Inc

Somers Point, New Jersey, United States

North Shore Univ Hosp / Div of Infectious Diseases

Manhasset, New York, United States

Univ of Texas Southwestern Med Ctr of Dallas

Dallas, Texas, United States

Houston Clinical Research Network

Houston, Texas, United States

Univ of Texas / Med School at Houston

Houston, Texas, United States

Univ of Texas Health Sciences Ctr

San Antonio, Texas, United States

Key Dates

Start Date

August 1, 1999

Last Updated

June 24, 2005

Conditions

HIV Infections

Interventions

Abacavir sulfate

DRUG

Efavirenz

DRUG

Emtricitabine

DRUG

Stavudine

DRUG

Skeletal Muscle Energetics and Fatiguability in Older Individuals

NCT04142047

HIVHIV Infections

View study

RECRUITINGPHASE3

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

NCT06694805

HIV Infections

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 24, 2005Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Comparison of Emtricitabine and Abacavir Used in a Three-Drug Combination in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

Inclusion Criteria

Skeletal Muscle Energetics and Fatiguability in Older Individuals

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

Clinic vs Clinic+Community Outreach HPV Self-Collection to Increase Cervical Screening in Women With HIV

Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR)

Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706

Comprehensive HIV and Harm Prevention Via Telehealth